Literature DB >> 21771990

Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management.

Colleen Hadigan1, Shyamasundaran Kottilil.   

Abstract

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) both emerged in the second half of the 20th century, and chronic infection with these agents is among the greatest challenges facing health care in the United States and worldwide. Despite tremendous advances in treatment and management of HIV and HCV, individuals with HIV/HCV coinfection experience a more complicated disease course and treatment. Recognition of the important role that host factors, such as IL28B genotype, have in response to HCV therapy and the emergence of new effective therapies for HCV are actively reshaping the standard of care. These advances may translate into more effective treatment and management of patients with chronic HCV and HIV coinfection in the years ahead.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771990     DOI: 10.1001/jama.2011.975

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  18 in total

1.  Systemic cytokine and interferon responsiveness Patterns in HIV and HCV mono and co-infections.

Authors:  Rafael Fernandez-Botran; Swati Joshi-Barve; Smita Ghare; Shirish Barve; Mary Young; Michael Plankey; Jose Bordon
Journal:  J Interferon Cytokine Res       Date:  2014-06-23       Impact factor: 2.607

2.  Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis.

Authors:  Patrick Georgoff; David Thomasson; Adeline Louie; Estee Fleischman; Lauren Dutcher; Haresh Mani; Shyamasundaran Kottilil; Caryn Morse; Lori Dodd; David Kleiner; Colleen Hadigan
Journal:  AJR Am J Roentgenol       Date:  2012-07       Impact factor: 3.959

Review 3.  Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Kirby; Kasha Singh; Edward J Mills; Graham Cooke; Adeeba Kamarulzaman; Philipp duCros
Journal:  Bull World Health Organ       Date:  2012-02-03       Impact factor: 9.408

4.  IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.

Authors:  Anu Osinusi; Aarthi Chary; Mark A Winters; Susanna Naggie; Henry Masur; Michael A Polis; Shyam Kottilil; Mark Holodniy
Journal:  J Med Virol       Date:  2012-10       Impact factor: 2.327

5.  Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.

Authors:  Long Zhang; David D Celentano; Nguyen Le Minh; Carl A Latkin; Shruti H Mehta; Constantine Frangakis; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Vu Minh Quan; Vivian F Go
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

6.  Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.

Authors:  A Rivero-Juarez; J A Mira; A Camacho; K Neukam; I Perez-Camacho; A Caruz; J Macias; J Torre-Cisneros; J A Pineda; A Rivero
Journal:  Infection       Date:  2012-10-14       Impact factor: 3.553

7.  Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.

Authors:  Emily K Funk; Ashton Shaffer; Bhavana Shivakumar; Michael Sneller; Michael A Polis; Henry Masur; Laura Heytens; Amy Nelson; Richard Kwan; Shyam Kottilil; Anita Kohli
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-14       Impact factor: 2.205

8.  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Authors:  María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino
Journal:  BMC Med       Date:  2013-01-08       Impact factor: 8.775

9.  Influence of healthcare-associated factors on the efficacy of hepatitis C therapy.

Authors:  Mohamed A Daw; Aghynya A Dau; Mohamed M Agnan
Journal:  ScientificWorldJournal       Date:  2012-12-27

10.  Association of interleukin-10 polymorphisms with chronic hepatitis C virus infection in a case-control study and its effect on the response to combined pegylated interferon/ribavirin therapy.

Authors:  A J Khan; V A Saraswat; G Choudhuri; D Parmar; T S Negi; S Mohindra
Journal:  Epidemiol Infect       Date:  2014-03-18       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.